Global Oncology Partnering Analysis 2014-2019 - Access to Over 3,500 Oncology Deal Records; Leading Oncology Deals by Value Since 2014

News provided by

Jan 28, 2020, 13:45 ET

DUBLIN, Jan. 28, 2020 /PRNewswire/ -- The "Global Oncology Partnering 2014-2019: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

Global Oncology Partnering 2014-2019 provides an understanding and access to the oncology partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in Oncology partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Oncology partnering agreement structure
Oncology partnering contract documents
Top Oncology deals by value
Most active Oncology dealmakers

The report provides a detailed understanding and analysis of how and why companies enter oncology partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors oncology technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest oncology agreements announced in the healthcare sector.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Oncology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Oncology deals.

The report presents financial deal terms values for Oncology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Oncology dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Oncology dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Oncology deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Oncology dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Oncology deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Oncology partnering deals by specific Oncology target announced since 2014. The chapter is organized by specific Oncology therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Oncology partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Oncology partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Oncology technologies and products.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all oncology partnering deals announced since 2014 including financial terms where available including over 3,500 links to online deal records of actual oncology partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Report Scope

This report is intended to provide the reader with an in-depth understanding and access to oncology trends and structure of deals entered into by leading companies worldwide.

The report includes:

Trends in oncology dealmaking in the biopharma industry since 2014
Analysis of oncology deal structure
Access to headline, upfront, milestone and royalty data
Access to over 3,500 oncology deal records
The leading oncology deals by value since 2014

The available deals are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report provides comprehensive access to available deals and contract documents for over 3,500 oncology deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are the sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Oncology dealmaking
2.1. Introduction
2.2. Oncology partnering over the years
2.3. Oncology partnering by deal type
2.4. Oncology partnering by industry sector
2.5. Oncology partnering by stage of development
2.6. Oncology partnering by technology type
2.7. Oncology partnering by therapeutic indication

Chapter 3 - Financial deal terms for Oncology partnering
3.1. Introduction
3.2. Disclosed financials terms for Oncology partnering
3.3. Oncology partnering headline values
3.4. Oncology deal upfront payments
3.5. Oncology deal milestone payments
3.6. Oncology royalty rates

Chapter 4 - Leading Oncology deals and dealmakers
4.1. Introduction
4.2. Most active in Oncology partnering
4.3. List of most active dealmakers in Oncology
4.4. Top Oncology deals by value

Chapter 5 - Oncology contract document directory
5.1. Introduction
5.2. Oncology partnering deals where contract document available

Chapter 6 - Oncology dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Oncology therapeutic target

Companies Mentioned

1ST Biotherapeutics
2A
2X Oncology
3B Pharmaceuticals
3DMed
3D Signatures
3M Drug Delivery Systems
3PrimeDx
3SBio
4D Pharma
4SC
14M Genomics
20/20 GeneSystems
48Hour Discovery
1717 Life Science Ventures
A*STAR Agency for Science
Technology and Research
A*STAR Bioinformatics Institute
A*STAR Bioprocessing Technology Institute
A*STAR Genome Institute of Singapore
A*STAR' Institute of Molecular and Cell Biology
AADi
aaiPharma
AB Analitica
Abbisko Therapeutics
Abbott Laboratories
Abbvie
Abcam
AbClon
Abcodia
Abcuro
Abilita Bio
Ability Pharmaceuticals
Abingdon Health
Abingworth Management
ABL Bio
Ablynx
Abpro
Abramson Cancer Center
Abreos Biosciences
Absorption Systems
ABX
Abzena
Academia Sinica
Academic and Community Cancer Research United
Academic Drug Discovery Consortium
Accelovance
Accenture
Access Health
Access Pharmaceuticals
Accord Healthcare
AccuGenomics
Accuray
Accu Reference Medical Laboratory
Accurexa
Accutest
ACEA Biosciences
AceCGT Life Science
Acentrus Specialty
Acerta Pharma
Acoustic MedSystems
Acrotech Biopharma
ACT Biotech
Actelion
ACT Genomics
Actinium Pharmaceuticals
Actinobac Biomed
Active Biotech
ACT Onocology
Acuity Pharmaceuticals
Adagene
Adaptiiv
Adaptimmune
Adaptive Biotechnologies
ADC Therapeutics
Adimab
Adlai Nortye
Admera Health
AdoRx Therapeutics
ADT Pharmaceuticals
Adult Brain Tumor Consortium
Aduro BioTech
AdvaMed
Advanced Accelerator Applications
Advanced Biological Laboratories
Advanced BioScience Laboratories
Advanced Cell Diagnostics
Advanced Cooling Therapy
Advanced Medical Isotope
Advanced Nuclear Medicine Ingredients
Advanced Proteome Therapeutics
Advanced Radiation Therapy
Advanomics
Advantagene
Advanz Pharma
Advaxis
Aegis Therapeutics
Aeglea BioTherapeutics
Aelan Cell Technologies
AEterna Zentaris
Aethlon Medical
Aetna
AffaMed Therapeutics
Affibody
Affigen
Affimed Therapeutics
Affinita Biotech
Affymetrix
Agalimmune
AGC Biologics
Agena Bioscience
Agency for Healthcare Research and Quality
Agendia
Agensys
Agenus Bio
Agilent Technologies
Agilvax
Agios Pharmaceuticals
AG Mednet
AgonOx
Aiforia Technologies
AIMM Therapeutics
Airmed Biopharma
AirXpanders
Aitbiotech
AiVita Biomedical
Akeso Biopharma
Akrevia Therapeutics
Akriveia Therapeutics
Akrivis Technologies
Albert Einstein College of Medicine
Albert Einstein Healthcare Network
Albumedix
Alcami
Alcyone Lifesciences
Aldevron
Alibaba Health
Alion Pharmaceuticals
Alkermes
Allcure Kangtai Proton Technology
Allegheny General Hospital
Allergan
Alliance for Biosecurity
Alliance For Cancer Care
Alliance For Clinical Trials In Oncology
Alliance Global FZ
Alliance Global Group
Alliance Healthcare Services
Alliance Oncology
Allied-Bristol Life Sciences
Alligator Bioscience
Allogene Therapeutics
Ally Bridge Group
Almac Diagnostics
Almac Discovery
Almac Group
Almirall
Alpha Cancer Technologies
Alpha Imaging
Alphamab
Alpine Immune Sciences
Altavant Sciences
Alteogen
Alteris
Altiora
Altor BioScience
Altum Pharmaceuticals
Altus Formulation
Alvogen
Alvotech
Amal Therapeutics
Amaran Biotechnology
Amarantus BioSciences
Amarna Therapeutics
Ambrx
Ambry Genetics
amcure
America's Choice Provider Network
American Association for Cancer Research
American Brain Tumor Association
American Cancer Society
American College of Radiology
American CryoStem
American Dental Association
American Health Imaging
American Liver Foundation
American Lung Association
American Skin Association
American Society of Clinical Oncology (ASCO)
American Society of Human Genetics
AmerisourceBergen
Amgen
Amneal Pharmaceuticals
AmorChem
Amoy Diagnostics
AmoyDx Diagnostics
AMPATH Oncology Institute
Amplitech
Amunix
Anaeropharma
Analogic
Analytical Bio-Chemistry Laboratories
Analytical Biological Services
Anam Hospital
AnaptysBio
Anchiano Therapeutics
Angelini Pharma
Angiex
Angiochem
Angiodynamics
Angle
Angsana Molecular & Diagnostics
AnHeart Therapeutics
Animatrix Capital
ANI Pharmaceuticals
Anixa Biosciences
Annias Immunotherapeutics
Anpac Bio-Medical Science
Antengene
Anthem Bluecross
Anthera Pharmaceuticals
Anthony Nolan
Antigen Express
Antikor Biopharma
Antitope
Apceth
APC Therapeutics
Apeiron Biologics
Aperion Biologics
Apexigen
APG Bio
Aphios
Apobiologix
Apocell
Apogee Biotechnology
Apogenix
ApolloBio
Apollo Hospitals Group
Appistry
Applied BioMath
Aprea
AptaBio Therapeutics
Aptamer Therapeutics
Aptarion biotech
Aptevo Therapeutics
Aptose Biosciences
Aqilion
Aquila BioMedical
Aranda Pharma
Aratana Therapeutics
Aravive Biologics
Arbor Vita
ArcherDX
ARCH Personalized Medicine Initiative
Arc Medical Design
Arcus Biosciences
Areva Med
arGEN-X
argenx
Argos Therapeutics
Ariad Pharmaceuticals
Ariana Pharma
Arisaph Pharmaceuticals
Arix Bioscience
and many more...

For more information about this report visit https://www.researchandmarkets.com/r/368s7u

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets